Bibliography
- TURPIE AGG, CHIN BSP, LIP GYH: Venous thromboembolism: pathophysiology, clinical features and prevention. Br. Med. 1 (2002) 325:887-890. An excellent overview of venous thromboembolism.
- CLAGETT GP, ANDERSON FA Jr, GEERTS W et al.: Prevention of venous thromboembolism. Chest (1998) 114:531S–560S.
- AGU 0, HAMILTON G, BAKER D: Graduated compression stockings in the prevention of venous thromboembolism. Br: J. Surg. (1999) 86(8):992–1004.
- KALODIKI EP, HOPPENSTEADT DA, NICOLAIDES AN et al.: Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randmised controlled trial. Int. Anglo' (1996) 15(2):162–168.
- MAYNARD MJ, SCULCO TP, GHELMAN B: Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin. Orthop. (1991) 273:125–130.
- HULL RD, PINEO GF, FRANCIS C et al: Low-molecular weight heparin prophylaxis using dalteparin in close proximity to surgery versus warfarin in hip arthroplasty patients: a double-blind randomized comparison. Arch. Intern. Med. (2000) 160:2199–2207.
- SAMAMA CM, VRAY M, BARRE J et al: Extended venous thromboembolism prophylaxis after total hip replacement: A comparison of low-molecular-weight heparin with oral anticoagulant. Arch. Intern. Med. (2002) 162:2191–2196.
- ERIKSSON BI, WILLE-JORGENSEN P, KALEBO P et al: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med. (1997) 337(19):1329–1335.
- LASSEN MR, BAUER KA, ERIKSSON BI, TURPIE AGG: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomised double - blind comparison. Lancet (2002) 359:1715–1720.
- GUSTAFSSON D, NYSTROM J-E, CARLSSON S et al.: The direct thrombin inhibitor megalatran and its oral pro-drug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. (2001) 101:171–181.
- •A good overview of melagatran and its properties.
- GUSTAFSSON D, ANTONSSON T, BYLUND R et al.: Effects of megalatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemostasis (1998) 79:110–118.
- •A good overview of melagatran and its properties.
- ELG M, GUSTAFSSON D, DEINUM J: The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb. Haemost. (1997) 78:1286–1292.
- METHA JL, CHEN L, NICHOLS WW et al.: Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. Cardiovasc. Pharmacol (1998) 31:345–351.
- ELG M, GUSTAFSSON D, CARLSSON S: Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. (1999) 94:187–197.
- WAHLANDER K, LAPIDUS L, OLSSON C-G et al: Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb. Res. (2002) 107:93–99.
- ERIKSSON BI, ARFWIDSSON AC, FRISON L et al.: A Dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb. Haemost. (2002) 87:231–237.
- ERIKSSON BI, BERGQVIST D, KALEBO P et al.: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (2002) 360:1441–1447.
- ••The METHRO II trial.
- FRANCIS CW, DAVIDSON BL, BERKOWITZ SD et al.: Ximelegatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann. Intern. Med. (2002) 137:648–655.
- DARIUS H: New developments in anticoagulation therapy for lone atrial fibrillation. Haemostaseoligie (2002) 22:30–35.